

CLAIM STATUS

1. (allowed) A method for treating a neoplasm comprising cells, comprising:
administering to said neoplasm an amount of a mutant human herpes simplex virus which is oncolytic to cells in said neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparan sulfate..
2. (allowed) A method of claim 1, wherein said virus comprises a deletion in the UL44 gene which codes for heparan binding of glycoprotein C polypeptide
3. (allowed) A method of claim 1, wherein said virus comprises a deletion of amino acids 33-123 in the UL44 gene.
4. (allowed) A method of claim 1, wherein said virus comprises an insertion in the UL44 gene which codes for heparan binding of glycoprotein C polypeptide
5. (allowed) A method of claim 1, wherein the parental strain of said virus is KOS.
6. (allowed) A method of claim 1, wherein said virus is gC-39.
7. (allowed) A method of claim 1, wherein said virus is impaired in its ability to infect, or attach to the surface of normal cells as compared to the wild-type parental strain.
8. (allowed) A method of claim 1, wherein said virus is impaired in its ability to infect neuronal cells as compared to the wild-type parental strain.
9. (allowed) A method of claim 1, wherein said neoplasm is an adenocarcinoma.

Onyx Pharmaceuticals
09/741, 127
amend 116

4

10. (allowed) A kit comprising a mutant human herpes simplex virus which is oncolytic to cells in a ncoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparan sulfate and a chemotherapeutic agent.

11. (cancelled).

12. (cancelled).

13. (cancelled).

Onyx Pharmaceuticals
09/741, 127
amend 116

5